Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tempest Therapeutics Inc (TPST)

Tempest Therapeutics Inc (TPST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,041
  • Shares Outstanding, K 43,642
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,490 K
  • EBIT $ -36 M
  • EBITDA $ -35 M
  • 60-Month Beta -1.78
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.07
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.53
  • Most Recent Earnings $-0.41 on 11/12/24
  • Next Earnings Date 11/13/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 161.30% ( +13.48%)
  • Historical Volatility 71.78%
  • IV Percentile 34%
  • IV Rank 34.45%
  • IV High 351.94% on 07/24/24
  • IV Low 61.10% on 07/03/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 166
  • Volume Avg (30-Day) 407
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 8,320
  • Open Int (30-Day) 9,185

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.24
  • Number of Estimates 3
  • High Estimate -0.19
  • Low Estimate -0.30
  • Prior Year -0.34
  • Growth Rate Est. (year over year) +29.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8000 +19.99%
on 11/18/24
1.2100 -20.67%
on 10/29/24
-0.1301 (-11.94%)
since 10/25/24
3-Month
0.8000 +19.99%
on 11/18/24
1.5900 -39.63%
on 10/16/24
-0.3801 (-28.37%)
since 08/27/24
52-Week
0.8000 +19.99%
on 11/18/24
6.0000 -84.00%
on 04/02/24
-2.8101 (-74.54%)
since 11/27/23

Most Recent Stories

More News
Tempest Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference on December 3, 2024

Tempest Therapeutics will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 3, 2024.Quiver AI SummaryTempest Therapeutics, Inc., a clinical-stage biotechnology company...

TPST : 0.9599 (+2.07%)
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

TPST : 0.9599 (+2.07%)
Tempest Therapeutics (TPST) Stock Jumps 83% on FDA Phase 3 Trial News

Tempest Therapeutics (NASDAQ: TPST), a clinical-stage biotechnology firm focused on innovative cancer therapies, announced a significant milestone on Thursday as it secured the U.S. Food and Drug Administration’s...

TPST : 0.9599 (+2.07%)
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

TPST : 0.9599 (+2.07%)
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

TPST : 0.9599 (+2.07%)
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

TPST : 0.9599 (+2.07%)
Tempest Extends Limited Duration Stockholder Rights Plan

TPST : 0.9599 (+2.07%)
Tempest Therapeutics (TPST) Stock Jumps 83% on FDA Phase 3 Trial News

Tempest Therapeutics (NASDAQ: TPST), a clinical-stage biotechnology firm focused on innovative cancer therapies, announced a significant milestone on Thursday as it secured the U.S. Food and Drug Administration’s...

TPST : 0.9599 (+2.07%)
MarketBeat Week in Review – 10/16 - 10/20

All the major indexes moved lower on Friday, making it a near certainty that stocks would post their worst week in a month; the bears are firmly in control

HRL : 31.92 (+0.95%)
CPB : 46.07 (-1.14%)
LMND : 49.16 (-1.54%)
UAA : 9.70 (+0.10%)
VFS : 4.26 (+7.85%)
TSLA : 332.89 (-1.58%)
TXN : 199.19 (-0.88%)
META : 569.20 (-0.76%)
DLTR : 71.50 (+3.44%)
NFLX : 877.34 (+0.54%)
DXCM : 78.10 (+0.21%)
TPST : 0.9599 (+2.07%)
The Secrets Behind a 4000% Biotech Stock Surge

Last Wednesday, shares of Tempest Therapeutics (NASDAQ: TPST), a small-cap stock you have probably never heard of, surged over 4000%.

TPST : 0.9599 (+2.07%)

Business Summary

Tempest Therapeutics Inc. is a clinical-stage oncology company developing potentially first-in-class therapeutics which combines both targeted and immune-mediated mechanisms. Tempest Therapeutics Inc., formerly known as Millendo Therapeutics Inc., is based in Calif.

See More

Key Turning Points

3rd Resistance Point 1.0378
2nd Resistance Point 1.0082
1st Resistance Point 0.9841
Last Price 0.9599
1st Support Level 0.9304
2nd Support Level 0.9008
3rd Support Level 0.8767

See More

52-Week High 6.0000
Fibonacci 61.8% 4.0136
Fibonacci 50% 3.4000
Fibonacci 38.2% 2.7864
Last Price 0.9599
52-Week Low 0.8000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar